In this podcast, Drs. Michelle Kittleson and Jan Griffin provide a practical overview of evaluation and management of transthyretin amyloid cardiomyopathy (ATTR-CM) based on ACC's 2025 Concise Clinical Guidance document the Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. The experts elaborate on key takeaways, including identifying cardiac and extra-cardiac features that raise suspicion, outlining the diagnostic pathway and screening strategies, and utilizing current disease-modifying therapies and heart failure management. Guidance on monitoring, determining treatment candidacy, and emerging future therapies is also discussed.
This podcast is supported by an educational grant from BridgeBio.
